We report the results of a pilot open-label trial of a tenofovir (TDF)/emtricitabine (FTC)/efavirenz (EFV) combination conducted in Dakar, Senegal. Forty HIV-1-infected patients, naive of antiretroviral treatment and without active opportunistic disease, were included and followed through 96 weeks. At weeks 48 and 96, respectively, 82.5% and 85% of patients had HIV-1 RNA <400 copies/mL (72.5% and 77.5% with HIV-1 RNA <50 copies/mL). Between baseline and week 96, the mean (SD) CD4 count increased from 126 (102) to 338 (155) cells/mm 3 . The mean (SD) creatinine clearance decreased from 92 (36) to 73 (19) mL/min (P ¼ .001). Treatment adherence was at least 94% at all scheduled visits. The efficacy and tolerability of a TDF/FTC/EFV combination were high and similar to those observed in Northern countries. This drug combination can be recommended in limited-resource countries, as did the World Health Organization (WHO) and should be made readily available as a fixed-dose combination.
Introduction
Access to antiretroviral therapy (ART) to treat HIV infection is a global public health priority, with special emphasis in developing countries. In sub-Saharan Africa, the number of patients who need highly active antiretroviral treatment (HAART) is likely to increase markedly over the next few years. 1, 2 Several trials and observational studies have demonstrated the efficacy of HAART in this setting. [3] [4] [5] However, antiretroviral (ARV) coverage remains inadequate in the developing world for many reasons, including the limited availability of simple regimens.
New ARV drugs that can be conveniently administered once daily have recently been licensed in industrialized countries and include the nucleotide reverse transcriptase inhibitor (NtRTI) tenofovir (TDF) and the nucleoside reverse transcriptase inhibitor (NRTI) emtricitabine (FTC). TDF has a prolonged serum half-life that enables once-daily dosing and has a unique resistance profile. In vitro studies have shown that TDF is active against mutant isolates that are resistant to zidovudine (AZT), didanosine (ddI), zalcitabine (ddC), abacavir (ABC), and the multinucleoside drug-resistant variants carrying the Q151M mutation. TDF has slightly increased ARV activity against HIV isolates with the M184V mutation associated with lamivudine (3TC) resistance. Although selection of the K65R mutation in reverse transcriptase is associated with 3-to 4-fold reductions in susceptibility, this mutation has been identified in only 2% of clinical isolates to date. 6 The combination of TDF/FTC/efavirenz (EFV) given once daily fulfilled the criteria for noninferiority at week 48 to a fixed dose of AZT and 3TC plus EFV given twice daily. 7 Because of its safety and resistance profiles associated with ease of use (once daily), recent World Health Organization (WHO) HIV treatment guidelines recommend TDF and FTC as preferred first-line treatment. 8 However, no data are available on the use of this triple regimen in sub-Saharan Africa, where the efficacy and tolerability of HAART regimens may be compromised by treatment initiation at an advanced state of immunodeficiency and by the high frequency of comorbidities.
We therefore conducted a pilot trial of the TDF/FTC/EFV combination in Dakar, Senegal, among treatment-naive patients.
Patients and Methods

Study Population
The inclusion criteria were documented HIV-1 infection, no previous ART, age at least 18 years, Karnofsky score >70%, and US Centers for Disease Control and Prevention (CDC) stage B or stage C with CD4 count <350 cells/mm 3 or stage A with CD4 count <200 cells/mm 3 . Patients classified as stage C because of a history of tuberculosis (TB) had to have a CD4 count <350 cells/mm 3 . Other inclusion criteria were a negative blood test for pregnancy and effective contraception among women patients, willingness to participate, and informed consent. The main exclusion criteria were HIV-2 infection, active opportunistic infections (OIs), hemoglobin <7 g/dL, platelets <50 000/mm 3 , creatinine clearance (Cockcroft-Gault) <50 mL/ min, prothrombin level <50%, and liver enzyme values more than 3 times the upper limit of normal.
Trial Design
This was a single-center prospective open-label 1-arm trial in which all patients received the following 3 drugs once daily at bedtime: TDF (245 mg, 1 tablet), FTC (200 mg, 1 tablet), and EFV (600 mg, 1 capsule). The daily EFV dose was increased to 800 mg for patients also receiving rifampin.
Patients received cotrimoxazole prophylaxis when needed, following 2003 WHO HIV treatment guidelines (www.who.int/3by5). The study was supported by the French National Agency for AIDS and Viral Hepatitis Research (ANRS). FTC and TDF were supplied by Gilead Sciences. At the end of the trial, patients in whom the treatment was effective were kept on the same regimen through the National Senegalese AIDS Program.
The patients were monitored at Fann Hospital, Dakar, Senegal, by 2 physicians from the Infectious Diseases Department. All data were recorded on an electronic case report form and exported to an electronic database for analysis.
The study was conducted in accordance with the Helsinski Declaration and was approved by the Senegalese ethics committee. Written informed consent was obtained from each patient after the aim of the study had been explained in the patient's native language.
Study Procedures
Physical examinations and laboratory analyses were conducted at screening, inclusion and follow-up at weeks 2, 4, 12, 24, 36, 48, 72, and 96. The screening evaluation included a medical history (CDC stage, concomitant medication, and other health problems) and a physical examination. Clinical status, adverse events, and concomitant medications were recorded at each visit. Clinical and biological adverse events were graded using the Agence Nationale de Recherche sur le Sida et les hépatites virales (ANRS) scale.
Blood cell counts, hemoglobin, biochemistry, CD4 and CD8 counts, and plasma HIV-1 RNA level were determined at baseline, after 1 month of follow-up (except for the CD4 count), and at weeks 12, 24, 36, 48, 72, and 96. Blood triglycerides, total cholesterol, and glucose were measured at baseline and at weeks 24, 48, 72, and 96. Women had a blood test for pregnancy at each visit.
The ARV drugs were supplied to each patient by the hospital pharmacist fortnightly during the first month and monthly thereafter during 96 weeks of follow-up. Adherence to treatment was assessed by the pharmacist at each treatment dispensation, using a questionnaire covering adherence during the previous 3 days and the previous month. Adherence was defined as the ratio of pills claimed to have been taken to the number of prescribed pills.
Quality of life was assessed by the physician every 3 months during the first 48 weeks of follow-up; the patients answered 2 questions concerning their current physical and emotional state by comparison with the previous year.
Laboratory Methods
Plasma HIV-1 RNA was measured in the virology laboratory of Hospital Le Dantec in Dakar, using the Amplicor HIV-1 1.5 or 2.0 assay (Roche Molecular Systems, Meylan, France), with a detection limit of 50 copies/mL. Routine laboratory tests and CD4 counts were performed in the laboratory of Fann Hospital, Dakar; CD4 cells were counted with the fluometric Facscount technique (Becton Dickinson). Creatinine clearance was calculated with the Cockcroft-Gault method using the patient's actual weight. 9
Endpoints and Statistical Analysis
The primary end point was the percentage of patients with plasma HIV-1 RNA <400 copies/mL at week 48. Secondary end points were the percentage of patients with plasma HIV-1 RNA <400 copies/mL at week 96, the percentage of patients with plasma HIV RNA <50 copies/mL at weeks 48 and 96, the CD4 count gain from baseline to weeks 48 and 96, weight change from baseline, the frequency and severity of adverse effects, treatment adherence, and quality of life.
The primary analysis was performed on an intent-to-treat (ITT) basis, losses to follow-up, deaths, and missing data being attributed to failure. An on-treatment analysis was also performed.
Continuous variables are expressed as mean and standard deviation or as median and interquartile range (IQR). Ninetyfive percent confidence intervals (CI) are provided for primary and secondary end points. Statistical analyses were performed with the Stata software package version 8 (College Station, Texas). status was poor (body mass index <18.5) in 31% of men and 25% of women. The median CD4 count was 111 cells/mm 3 (IQR: 31-227 cells/ mm 3 ) and 72.5% of patients had a CD4 count below 200 cells/ mm 3 . The median plasma HIV-1 RNA level was 5.33 log 10 copies/mL (IQR: 4.98-5.88). Five patients had detectable HBs antigen. None of the patients had antibodies to hepatitis C virus.
Results
Baseline Characteristics of the Patients
Virological and Immunological Responses
At week 48, 82.5% of patients (95% CI: 76.5%-88.5%) in the ITT population (n ¼ 40) had an HIV-1 RNA plasma levels below 400 copies/mL: this was 85% at week 96. At weeks 48 and 96, 72.5% and 77.5% of patients had HIV-1 RNA plasma level below 50 copies/mL by ITT analysis (Figure 1 ) and 82.9% and 88.2% by on-treatment analysis (n ¼ 35), respectively.
The mean (SD) CD4 count increased between baseline and week 96 from 126 (102) to 338 (155) cells/mm 3 ; the mean (SD) CD4 gain was 164 (126) and 212 (53) cells/mm 3 at weeks 48 and 96, respectively (Figure 2 ). At weeks 48 and 96, 55% and 88.6% of patients had CD4 counts >200 cells/mm 3 , respectively.
Clinical Outcomes
Thirty-five patients completed the 96 weeks of follow-up. Two patients were lost to follow-up: 1 left Senegal, while the other did not return calls and had given a wrong address.
Three deaths occurred during the first 3 months of treatment. Death was due to extrapulmonary TB in 1 case and to septic shock (no identified germ) in another case; the cause of death was not reported in the third case (the patient died outside of Dakar). These 3 patients had very low CD4 counts at baseline (<5 cells/mm 3 ).
Mean (SD) weight gain was 5.6 (1.2) kg for men and 5.5 (1.0) kg for women at week 96. One pregnancy was diagnosed after 3 months of treatment and EFV was switched to nevirapine (NVP). The infant was stillborn at month 6 of pregnancy; the results of physical examination were not available.
Clinical Adverse Events
Fifty adverse events were reported during the first month of follow-up, of which 60% were dizziness of grade 2 or 3, probably related to EFV. The other adverse events were episodes of diarrhea or nausea lasting less than 1 week. Few patients had asthenia. One severe adverse event (grade 4 dizziness attributed to EFV) occurred at month 3 and led to treatment discontinuation. This patient was hospitalized and died of probable disseminated tuberculosis. No other permanent or temporary treatment discontinuations were needed due to severe adverse events. No severe adverse events were reported after the first 3 months of treatment.
Biological Safety
No significant changes in hematological parameters (white blood cells, platelets, and hemoglobin), liver enzymes, or blood glucose levels were observed. Lipid parameters remained normal from baseline to week 96, with stable mean (SD) fasting total cholesterol levels: 160 (47) 
Adherence and Quality of Life
Adherence was assessed on 178 occasions; 24% of patients declared having missed at least 1 intake during the previous 3 days and 49% in the previous month. Nevertheless, the level of adherence was never below 94% at any scheduled visit. Missing drug intakes were attributed by the patients to ''treatment lapses'' in 63% of cases. In 71% of cases, the patients had forgotten to take all 3 pills. When only 1 pill was forgotten, it was EFV in 96% of cases.
Quality of life improved during the study. At week 48, 80% of the patients declared that their quality of life had improved (slightly or markedly) in comparison with the previous year.
Discussion
The ARV regimen evaluated in this trial has been already studied in Northern countries. In Gilead Science's Study 934, respectively, 84% and 80% of patients treated with the TDF/FTC/EFV regimen had viral loads <400 and <50 copies/mL at week 48, proportions similar to those observed in our trial. 7 After 48 weeks, the CD4 count had risen by an average of 160 cells/mm 3 in these Senegalese patients, to be compared to 190 cells/mm 3 in Study 934. It should be noted that these good results were obtained despite the fact that most patients had advanced HIV disease with high viral loads and low CD4 counts at baseline, placing them at a high risk of OIs and death. In addition, the 35 patients who completed the 96-week follow-up without treatment modifications reached a high rate of undetectable viral load and increased CD4 count. We previously observed a similar rate of success in a trial conducted in Dakar, testing a oncedaily regimen combining ddI, 3TC, and EFV in patients with similar baseline characteristics. 10 Three patients died during the first month of follow-up. However, all were already at a highly advanced stage of HIV disease at inclusion (CDC stage C and CD4 below 5 cells/ mm 3 ). As in the national Senegalese cohort, in which the mortality rate during the first year after HAART initiation was 17.4% (95% CI, 13.9%-21.5%), the causes of death in these 3 cases were mycobacterial infection and septicemia. 11 A good correlation between virological success and clinical improvement was observed: the mean weight of patients increased and no OIs occurred after the first 3 months of treatment. Dizziness related to EFV was frequent but observed only during the first month of treatment. EFV has become a leading drug for ART regimens. 12 Because of EFV's potential teratogenicity, contraception was strongly recommended in this trial. However, 1 pregnancy occurred and ended in miscarriage. No link with EFV could be established.
There were no significant changes in hematological parameters and lipid parameters remained normal.
A slight but significant decrease in creatinine clearance was observed. A decrease in the glomerular filtration rate (GFR) has been reported with TDF in several studies but rarely requires treatment discontinuation. 13, 14 Renal insufficiency and other renal adverse events such as Fanconi syndrome have been reported with TDF-containing ARV regimens, but the overall renal safety profile of TDF remains favorable in long-term studies. [15] [16] [17] In the DART trial, conducted in Uganda and Zimbabwe, only 1.6% of patients treated with TDF-containing regimens had a grade 3 to 4 GFR reduction: the GFR fell by a mean of 2.5 mL/min per 1.73 m 2 during the first 48 weeks and the prevalence of GFR reductions was the same in the AZT/3TC/ ABC and AZT/3TC/NVP groups. 18 A thorough renal evaluation could not be performed in our trial to better understand the mechanism of GFR changes. However, our observations indicate that special attention on renal function should be given with at least plasma creatinine measurements when TDF is introduced, particularly in patients with risk factors for renal failure such as high blood pressure, diabetes, dehydration, or receiving nephrotoxic treatment.
Another aim of our study was to evaluate the impact of a once-daily regimen on adherence. Indeed, both adherence and quality of life were good. Adherence was probably bolstered by the free access, the convenience, and the good clinical tolerance of this regimen. In addition, close medicosocial support was offered in the context of this pilot trial. A long-term assessment of adherence is warranted to determine whether adherence declines over time, as suggested by recent longitudinal studies conducted in West Africa. 4 In 2006, the WHO recommended the TDF/FTC/EFV combination as a preferred first-line regimen. 8 TDF is now included as a preferred first-line NtRTI because of its efficacy, ease of use, safety profile, and unique resistance profile. This is a change from the WHO's 2003 HIV treatment guidelines, which recommended reserving the use of TDF as part of second-line regimens.
This change in WHO guidelines is supported by our results, especially given the risk of anemia associated with AZT and the risk of lipoatrophy associated with AZT and stavudine (d4T). Also in support of this change is a recent study in Zambia performed by Mwango et al in 13 546 treatment-naive adult patients, which suggested that TDF was better tolerated than d4T and AZT in this setting. 19 The combinations of d4T/3TC/NVP, AZT/3TC/NVP, and AZT/3TC/EFV are currently the preferred first-line regimens for patients in resource-limited countries. 20 As the TDF/FTC/ EFV regimen will be available soon as a fixed-dose combination in developing countries, issues relating to cost, accessibility, and renal toxicity need to be examined in long-term cohort studies.
